DBV Technologies at AAAAI/WAO Congress to Present Advances in Peanut Allergy

DBV Technologies announces its participation at the AAAAI/WAO conference in San Diego. David Fleischer will present results at M60 from the PEOPLE study, an extension of the PEPITES study in children with peanut allergy. The percentage of responders to treatment with the VIASKIN® peanut patch has increased significantly. At M60, 73.3% of participants show a positive response.

The studies also show an increase in participants reaching high doses of reactogens, while highlighting a decrease in adverse events. The patch, which shows promise for food desensitization, will also be discussed at an AAAII symposium. DBV intends to strengthen its regulatory submissions to broaden the accessibility of the VIASKIN® peanut patch.